Skip to Content
 

News: Pancreatic Cancer

Pancreatic cancer development

Saturday, September 2nd, 2017

Pancreatic ductal carcinoma (PDAC) is one of the most lethal types of cancer, with new therapeutic options needed. Sergey Novitskiy, M.D., Ph.D., and colleagues investigated the immune response during the development of aggressive PDAC in an animal model of the disease.

Free seminar on multiple endocrine neoplasia Type I and II set for Feb. 4

Thursday, January 26th, 2017

Multiple endocrine neoplasia (MEN) Type I and Type II, disorders that affect the endocrine system, will be discussed at a free seminar sponsored by Vanderbilt University Medical Center (VUMC) and American Multiple Endocrine Neoplasia Support (AMENSupport) on Saturday, Feb. 4. The program is designed to educate patients, family members and medical personnel and to provide […]

Metastatic pancreatic cancer ‘reprograms’ for malignancy

Thursday, January 19th, 2017

Metastatic pancreatic cancer — cancer that has spread from the pancreas to other tissues and is responsible for most patient deaths — changes its metabolism and is “reprogrammed” for optimal malignancy, according to new findings reported Jan. 16 in Nature Genetics. It may be possible to reverse the malignant reprogramming to treat metastatic pancreatic cancer, […]

Chemo better option following pancreatic cancer surgery: study

Thursday, February 25th, 2016

A multicenter study led by Vanderbilt University Medical Center (VUMC) investigators found that pancreatic cancer patients who underwent surgery and received chemotherapy lived longer and had fewer cancer recurrences in other parts of the body than patients who also received chemoradiation therapy. The study led by Alexander Parikh, M.D., MPH, associate professor of Surgery and […]

Biomarker for intestinal tumors

Thursday, October 22nd, 2015

The incidence of pancreatic and small intestinal neuroendocrine tumors (NETs) has risen over the past decade. NETs are the second most common cancers in the small intestine and pancreas and are frequently associated with liver metastasis. Safia Salaria, M.D., and colleagues examined expression of CD24 – a biomarker for normal and cancer stem cells – […]

Pancreatic cancer lecture June 18

Friday, June 5th, 2015

Patients and families who want to learn more about treatments and research efforts in pancreatic cancer are invited to attend a free event Thurs., June 18, 6 – 8 p.m., at the Nashville Marriott at Vanderbilt University, 2555 West End Ave. The educational seminar, sponsored by the Pancreatic Cancer Action Network, features a presentation by […]

Cancer signaling pathway blocker

Friday, April 10th, 2015

Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer. Abnormal regulation of this pathway leads to several human malignancies, including small cell lung cancer and pancreatic cancer, and therefore it is a potential drug target for cancer. Small molecules have […]

NCI report shows U.S. cancer deaths on decline

Thursday, April 2nd, 2015

The death rates for most forms of cancer continue to decline at a modest pace among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer 1975 – 2011. The report from the National Cancer Institute, a division of the National Institutes of Health, […]

Cancer survival improvements vary by age, race

Thursday, February 26th, 2015

Improvements in cancer diagnosis and treatment have led to longer survival for most cancer patients in the United States. However, the improvement in survival was substantially greater among younger patients and those who are white in most of the cancers studied, according to new research by Vanderbilt University investigators. The study was published online recently […]

Grant bolsters pancreatic cancer drug discovery

Thursday, January 29th, 2015

The Lustgarten Foundation has awarded a $1.5 million Research Investigator Grant to Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry, for research designed to discover new drugs for the treatment of pancreatic cancer. This is Fesik’s second three-year award from the Lustgarten Foundation in support of his research targeting K-Ras, a protein mutated in […]

Next Page »